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Systemic delivery and Spect/
ct in vivo imaging of 125i-labelled 
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models of pancreatic cancer
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early phase clinical trials have demonstrated good therapeutic index for oncolytic adenoviruses in 
patients with solid tumours when administered intratumorally, resulting in local tumour elimination. 
entrapment and binding of adenovirus to erythrocytes, blood factors, and neutralising antibodies 
have prevented efficient systemic delivery and targeting of distant lesions in the clinic. We previously 
generated the novel replication-selective Ad-3∆-A20T to improve tumour targeting by increasing 
the viral dose at distant sites. Here, we developed a protocol to directly radiolabel the virus for rapid 
and sensitive detection by single-photon emitted computed tomography (Spect/ct) providing a 
convenient method for determining biodistribution following intravenous administration in murine 
models. Longitudinal whole-body scans, demonstrated efficient viral uptake in pancreatic Suit-2 and 
Panc04.03 xenografts with trace amounts of 125I-Ad-3∆-A20T up to 48 h after tail vein delivery. Hepatic 
and splenic radioactivity decreased over time. Analysis of tissues harvested at the end of the study, 
confirmed potency and selectivity of mutant viruses. Ad-3∆-A20T-treated animals showed higher viral 
genome copy numbers and E1A gene expression in tumors than in liver and spleen compared to Ad5wt. 
our direct radiolabeling approach, allows for immediate screening of novel oncolytic adenoviruses and 
selection of optimal viral genome alterations to generate improved mutants.
A promising novel strategy to eliminate solid tumors is the development of cancer-selective, replicating (onco-
lytic) adenoviral mutants. To date, several adenoviral mutants have been evaluated in clinical trials with demon-
strated safety, tumor selectivity and efficacy in conjunction with standard of care interventions1–3. In most trials, 
viruses were administered intratumorally. However, there is a need to further develop the viruses for efficient 
systemic delivery in order to reach deep and distant metastatic lesions. Major obstacles include the high-affinity 
binding to erythrocytes and blood factors, in addition to rapid elimination by hepatic Kupffer cells that greatly 
decrease the available dose at tumour sites4–7. Much research is aimed at overcoming these hurdles by develop-
ing novel mutants with prolonged circulatory half-life to maximise viral concentrations at the tumour sites1,8–10. 
Biodistribution is usually determined in preclinical in vivo models by harvesting tissues from numerous animals 
at multiple time points to quantify tumour and tissue uptake. In the current study, we developed a novel strategy 
to select for optimal mutants by rapid monitoring of viral distribution in individual live animals over time without 
the need for tissue harvesting at every time point.
We recently modified our potent replication-selective oncolytic adenovirus Ad∆∆11, to generate a novel 
mutant, Ad-3∆-A20T with attenuated erythrocyte and blood factor binding and specific targeting to pancreatic 
ductal adenocarcinomas (PDAC)12. The de-targeting modifications reduced viral association to human eryth-
rocytes and complement through ablation of viral fibre-binding to the Coxsackie and Adenovirus Receptor 
(CAR) and Complement Receptor 1 (CR-1)13. To further increase tumour-specific uptake, a 20-amino acid 
integrin-binding peptide (A20; A20FMDV2) was expressed in the viral fibre-knob12. This peptide, derived from 
the foot-and-mouth-disease-virus (FMDV), selectively binds to αvß6-integrins with high affinity (KD = 0.2nM) 
via the Arg-Gly-Asp (RGD)-domain14,15. The αvß6-integrins are frequently overexpressed in pancreatic, breast 
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and colorectal tumours with negligible expression in normal cells16–18. Both Ad-3∆-A20T and the αvß6-integrin 
targeted wild type virus Ad5A2019,20 preferentially infect αvß6-integrin expressing cells while uptake via 
the typical Ad5-pathway through αvß3- or αvß5-integrins, is significantly less12. The deletions in the highly 
cancer-selective and efficacious Ad∆∆ virus in combination with de- and re-targeting modifications resulted in 
the generation of the PDAC-selective oncolytic mutant Ad-3∆-A20T, an improved clinical candidate for systemic 
delivery12.
In the current study, we took advantage of the high levels of αvß6-integrins in human PDAC cell lines, and 
determined viral distribution in xenograft tumours after systemic delivery of the re-targeted and 125I-labelled 
mutants using single photon emission computed tomography (SPECT/CT). Three key areas were investigated 
in the murine models: (1) the feasibility of radiolabelling adenoviral mutants; (2) the suitability of 125I-labelled 
viruses for imaging and biodistribution studies; and (3) whether this is achievable without the need to con-
duct any further genetic alterations to the virus. A common, fast and easy method for radiolabelling of proteins 
involves incorporating 125I into Tyr-residues which allow for sensitive imaging detection21. However, this method 
is typically incompatible with biologically active viruses because it is usually performed under non-physiological 
reaction conditions which include optimal pH and buffer compositions that greatly reduce viral potency22. We 
hypothesised that small animal live imaging technology, SPECT/CT and MRI would rapidly inform on biodis-
tribution and tissue uptake of virus. Imaging in combination with positive detection of viral protein expression 
and replication/spread at tissue sites would allow for quicker identification of optimal viral mutations. Once iden-
tified, these can be further developed into clinically safe and potent therapies. Longitudinal distribution studies 
often require the sacrifice of multiple animals to analyse harvested tissues at specific time-points and our strategy 
could potentially provide an economical solution by shortening the time required for screening viral mutants in 
addition to reducing the number of animals per study. Imaging technology and quantification of radioactively 
labelled compounds have frequently been used in the discovery and development phases of peptides for example, 
[18F]fluorobenzoyl-A20FMDV2 for αvß6-integrins17, 18F-, 11C- and 123I-labelled ligands for the serotonin trans-
porter23 and the somatostatin analogue 111In-octreotide24. Our findings suggest that this strategy can be extended 
to actively replicating viruses.
The sequential steps described in this study demonstrate a novel approach for allowing the efficient screening 
of novel replication-selective adenoviral mutants during the preclinical phase of biotherapeutics development 
in vivo. We highlight the positive practicalities of directly labelling adenoviral mutants with 125I with retained 
activity for subsequent SPECT/CT image analysis in small animals. We propose a method that can swiftly inform 
on whole-body distribution, the location of experimental tumours and potential off-target infection sites. In 
combination with additional biodistribution and mechanistic studies, this method can provide essential data for 
safe clinical translation.
Results
optimised 125i radiolabelling conditions retains adenoviral functions. To efficiently radiolabel 
adenovirus with 125I, we considered the optimal conditions required for the reaction when combining the virus, 
oxidising agent, and radioisotope. The optimal performance of each of these is dependent on specific buffering 
conditions at certain pH levels. For example, the activity of Ad5 is optimal under physiological conditions, pH7.2-
7.825–27. Outside this range the bioactivity of Ad5 is reduced, primarily due to virion aggregation when pH level is 
lowered from pH8 to pH428. The radioisotope, Na125I is commercially available in the form of NaI/0.04 M NaOH 
and is stored at pH10-12 to preserve stability whereas the oxidising reagent (Iodogen) operates most efficiently at 
pH6.5 and is less efficient at higher pH29,30. It was therefore necessary to identify the optimal pH at which all three 
reagents were most compatible to perform the radiolabelling process. An overview of the labelling procedure is 
summarised in Fig. 1A, which include details of the experimental tests used at the earlier stages of protocol devel-
opment for optimisation purposes.
We tested various reaction conditions in the absence of radioactivity by replacing Na125I in 0.04 M NaOH 
with non-radioactive NaI in 0.04 M NaOH, to determine the preservation of viral infectivity and replication. The 
infectivity of I-labelled Ad5A20 (expressing EGFP) in the αvß6-integrin expressing Panc04.03 cells was analysed 
by flow cytometry (Supplementary Fig. 1A). Viral infection decreased from 42% (positive control) to 15% as a 
direct consequence of Iodogen exposure, an essential step in the protocol, used to oxidise the NaI prior to virus 
labelling. A further reduction in infectivity was observed upon addition of NaI/NaOH, due to the alkalinity of 
NaOH (pH10-12). The addition of 200 mM Tris-HCl (pH6.8 or pH4.0; dependent on batch of Na125I) lowered 
the final pH to 7.2-7.8 during the oxidation step and thereby partially restored viral infectivity (Supplementary 
Fig. 1B). Moreover, direct exposure of the virus to Iodogen greatly decreased the viral activity. However, trans-
ferral of the oxidised Na125I from the Iodogen tube to a tube containing only the virus and buffer eliminated 
viral oxidation. We applied the established optimal conditions (pH7.4-7.8 and 100 mM Tris pH4.0) to evalu-
ate infection and replication of our cancer-selective Ad-3∆-A20T labelled with non-radioactive NaI in cultured 
Suit-2 cells. Infection with I-Ad-3∆-A20T at 100ppc, resulted in 42 ± 3% of infected cells compared to 58 ± 4% 
for the non-labelled mock control at 24 h (Fig. 1B; left panel). Comparable levels of replication were observed at 
24 h, 2.1 × 107 ± 3.5 × 106 pfu/ml (non-labelled) and 2.2 × 107 ± 0.9 × 107 pfu/ml (labelled) which increased to 
1.6 × 108 ± 0.8 × 108 pfu/ml and 6.3 × 107 ± 1.1 × 107 pfu/ml, respectively by 48 h (Fig. 1B; right panel).
Next, we used Na125I under the same conditions to evaluate the efficiency of the labelling reaction. The specific 
activity of free 125I versus virus-bound 125I was determined by thin layer chromatography (TLC) (Fig. 1C). The 
three viruses used in this study, Ad5A20, Ad-3∆-A20T, and Ad5wt showed labelling efficiencies of 14.2–71.3% 
with the lowest specific activity for Ad5A20 (Fig. 1C). We observed a dependency on high virus concentra-
tions for higher levels of radiolabelling, explaining the lower specific activity for Ad5A20 that had the lowest 
viral stock concentration. The sample was electrophoresed by SDS-PAGE to verify that the labelled material was 
indeed 125I-virus (Fig. 1D). Three discrete radioactive bands were identified with two corresponding to the major 
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adenoviral capsid proteins; hexon (108 kDa), penton (63.3 kDa) and fibre (61.5 kDa) and a third band of ≤10 kDa 
representing the remaining free 125I in the sample and 125I-Tyr. To separate labelled virus from non-incorporated 
125I, column purification was performed. Although pure 125I-labelled virus was successfully isolated, the yield was 
poor (<25% of functional virus) and its use was subsequently discontinued (Fig. 1D; right panel).
In conclusion, the adapted labelling protocol had minimal effects on viral function; infection and replication 
rates remained largely unaffected. Although, the modified protocol is not optimal for the iodination reaction, 
sufficient 125I for imaging analysis was incorporated in the viral capsid proteins (see below).
Detection of 125I-Ad5A20 in pancreatic αvß6-integrin-expressing Panc04.03 xenografts after 
systemic delivery. We previously determined αvß6-integrin expression in 15 human pancreatic ductal ade-
nocarcinoma (PDAC) cell lines and the highest levels were detected in Panc04.03 cells12. Subcutaneous inocu-
lation of Panc04.03 cells in immune-deficient mice formed small tumours (18–50 µl) after ≥3 weeks with the 
support of Matrigel. Three mice with bilateral tumours were selected for systemic administration of 125I-Ad5A20 
(8.2 × 109 vp/animal; 10.8 MBq/animal) via tail vein injection and were imaged by SPECT/CT (one representative 
mouse; Fig. 2A, additional images in Supplementary Fig. 2A). The viral particles of 125I-Ad5A20 were detected 
in tumours at all tested time points (30 min, 2 h, and 4 h after injection), indicating that sufficient amounts had 
Figure 1. Flow diagram illustrates the labelling of adenoviral mutants with Na125I using Iodogen followed 
by down-stream processing. (A) In a typical reaction, 20–27 µl of Tris-HCl (200 mM, pH6.8) was added to an 
Iodogen tube followed by 25–33.3 µl Na125I (85–123 MBq) in 0.04 M NaOH pH11 and incubated for 2 min. 
This was followed by the addition of 1.23 × 108–2.62 × 1010 viral particles (vp) in 200–267 µl Tris-Cl (10 mM 
pH7.4) corresponding to 7.2 µg–7.65 µg viral proteins. The iodination reaction was terminated after 2.5 min by 
transferring the mixture to a new tube where it was diluted for in vivo imaging. For in vitro analytical assays, 
10 µl Tyrosine (10 µg) in Tris-Cl pH7.4 was added to quench the reaction, followed by column purification 
(Virabind). In the final optimised protocol Tris-HCl (200 mM, pH6.8) and 25–33.3 µl Na125I (85–123 MBq) in 
0.04 M NaOH pH11 were incubated in the Iodogen tube for 2 min and transferred to a new tube containing the 
virus as above and incubated for another 2.5 min. (B) Infectivity and replication in Suit-2 cells comparing non-
radioactive labelled I-Ad-3∆-A20T (I-Ad) and mock-infected non-labelled Ad-3∆-A20T (Ad). The reaction 
conditions were identical to those used for the radioactive 125I-incorporation. Infectivity was determined by a 
specific mouse anti-E1A antibody and detected by secondary anti-mouse FITC-coupled antibodies 24 h post-
infection (100 ppc) by flow cytometry (left panel). Viral replication was determined 24 h and 48 h post infection 
(100 ppc; per infection) (right panel). Averages ± SD, n = 2. (C) Aliquots (1 µl) of the reaction mixtures were 
analysed by instant thin layer chromatography (iTLC-SG) in 85% MeOH/H2O. Typical incorporation of 125I into 
the adenoviral capsid proteins were initially 14% (left TLC) and after optimization of pH and labelling protocols 
35–71% (middle and right TLC). (D) Aliquots (10 µl) of the reaction mixture were analysed on a 4–12% 
denaturing polyacrylamide gradient gel (SDS-PAGE) and viral coat proteins were identified using a molecular 
weight ladder matched to the radiograms. In some studies, the reaction mixture was purified on VirabindTM 
columns and the eluate containing 125I-Ad5 (400 µl) was analysed. The recovery yields of virus after Virabind 
purification were very low and only used in analytical assays. (C,D) Representative data.
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reached the tumour tissue in vivo. High uptake of radioactivity was also observed in the liver and gastrointestinal 
tract that decreased from 2 h onwards, and likely reflected the presence of free 125I in the injection mixture (<60% 
of free 125I) in addition to non-specific hepatic elimination of virus and label (Supplementary Fig. 2B). Subsequent 
image quantification was performed at later time points (24–48 h) to circumvent the initial non-specific abdom-
inal (mainly hepatic) accumulation/clearance of free 125I and 125I-Ad5A20 allowing for more accurate measure-
ment of tumour-associated radioactivity after imaging.
Accumulation of 125I-Ad5A20 in Suit-2 pancreatic tumour xenografts up to 24h after systemic 
delivery. We have previously established in vivo subcutaneous xenograft models using the human pancreatic 
αvß6- and αvß5- integrin expressing cancer cell line, Suit-212,31. All subsequent in vivo studies were performed 
using this model since they rapidly and consistently generate reproducible subcutaneous tumours; 100–200 µl 
in 2–3 weeks (Fig. 2B left; MRI image). 125I-Ad5A20 was prepared to 2.5 mBq/vp whereby 39% of 125I in the 
reaction mixture was incorporated into the virus. A total of 7 × 109 vp of 125I-Ad5A20 was injected via the tail 
vein in each mouse (n = 3). The majority of radioactivity was detected in liver and spleen 4 h after administration 
(Supplementary Fig. 2C) that markedly decreased after 24 h when radioactivity levels were higher in tumours 
Figure 2. 125I-Ad5A20 accumulates in Panc04.03 and Suit-2 pancreatic tumour xenografts after tail vein 
injection and imaged by SPECT/CT. (A) One animal with small bilateral subcutaneous and internal Panc04.03 
tumours imaged by SPECT/CT. The αvβ6-retargeted, and radioactively labelled 125I-Ad5A20 mutant 
(8.2 × 109 vp/animal; 10.8 MBq/animal) was injected via the tail vein and imaged after 30 min, 2 h and 4 h. White 
solid arrows indicate subcutaneous tumour; white dashed arrows indicate internal tumour, one representative 
animal shown, n = 3. (B) Left panel; T2-weighted MRI image of one representative animal with a subcutaneous 
Suit-2 tumour in one flank indicated by white arrow, prior to virus administration. Right panel; Intravenous 
administration of the αvβ6-retargeted and radioactively labelled 125I-Ad5A20 in 200 µl (7 × 109 vp of 2.5 mBq/
vp) in the same animal, imaged by SPECT/CT 24 h later. White arrows indicate tumour; white open arrow 
indicate bladder, one representative animal shown, n = 3. (A,B) The scale for all SPECT/CT images is 0.006–
0.0225 kBq.
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than in hepatic tissue (one representative animal in coronal and transverse views, SPECT/CT images; Fig. 2B 
right). Whilst the radioactivity associated with the liver, spleen and gastrointestinal tract decreased over time 
(4–24 h), levels in urine increased (Fig. 2B, additional images in Supplementary Fig. 3A).
Collectively, these studies demonstrate that the retargeted Ad5A20 quickly reached the tumours after sys-
temic delivery and was maintained up to 24 h. Additionally, tumour volumes estimated by the MRI survey scan 
correlated with end point volume (tumour weight) (160 µl in Fig. 2B), and was similar to calliper measurements 
(140 µl). Combining calliper measurements with MRI and SPECT/CT imaging is therefore a valuable strategy for 
determining viral efficacy, internal tumour growth and tissue distribution, respectively, over time.
Rapid uptake of the 125I-labelled oncolytic mutant Ad-3∆-A20T and Adwt in Suit-2 pancreatic 
tumour xenografts followed by efficient elimination by liver and spleen. Direct intratumoral 
administration of Adwt or our novel, retargeted replication-selective Ad-3∆-A20T mutant caused significant 
inhibition of tumour growth in Suit-2 xenograft models (18d; Fig. 3A)12. The feasibility of intravenous delivery 
of Ad-3∆-A20T was investigated using 125I-labelled virus in conjunction with SPECT/CT imaging. 125I-Ad5wt 
or 125I-Ad-3∆-A20T were administered via the tail vein (7 × 109 vp) in animals with Suit-2 xenografts (n = 4/
group). Radioactivity was detected in tumours, liver and spleen from 4 to 48 h (125I-Ad-3∆-A20T, 24 and 48 h and 
125I-Adwt, 48 h; Fig. 3B, additional images Supplementary Fig. 3B). After correcting for injected dose (% radio-
activity incorporated into virus and total amount administered) and tissue weight at the end of the study, quanti-
fication of the SPECT/CT images showed no significant differences in tumour uptake between treatment groups 
(Fig. 4A; left panel) (Liver; Supplementary Fig. 4). Tumour to liver ratios of radioactivity were also similar at these 
early time points (Fig. 4A; right panel). These observations were verified by direct measurements of radioactivity 
in tissues harvested at the end of the study (48 h) (Fig. 4B).
More potent viral E1A-expression in Suit-2 tumours after systemic delivery of the oncolytic 
mutant Ad-3∆-A20T than with Adwt. To investigate whether tissue-associated radioactivity correspond 
to the presence of virus, expression of the early viral gene E1A was determined in tumour and spleen tissues at the 
end of the study. Interestingly, animals treated with 125I-Ad-3∆-A20T presented with higher levels of the E1A pro-
tein in tumours, and lower levels in spleen compared to tissues harvested from animals treated with 125I-Ad5wt 
(Fig. 5A, complete immunoblot Supplementary Fig. 6). Contrastingly, the radioactivity levels in both treatment 
groups was similar (Fig. 4A,B). These findings suggest that the initial tumour-associated radioactivity is a result 
of virus distribution in the tumour microenvironment by the “leaky” vasculature often associated with tumours. 
Following the accumulation of virus in the tumours, cellular uptake of both 125I-Adwt and 125I-Ad-3∆-A20T 
rapidly proceeds which is dependent on multiple integrins. In the case of 125I-Ad-3∆-A20T, the virus can enter 
the cell via specific binding to the αvβ6-integrin receptor, whereas αvβ3 and αvβ5 integrins which are highly 
expressed on Suit-2 cells, provide additional routes for cellular entry while 125I-Adwt enter only through αvβ3 
and αvβ5 integrins. However, the higher levels of E1A-expression in tumours infected with 125I-Ad-3∆-A20T at 
Figure 3. Biodistribution of the novel retargeted oncolytic mutant 125I-Ad-3∆-A20T and 125I-Ad5A20 after 
intravenous delivery. (A) Suit-2 cells (1 × 106 cells) were inoculated subcutaneously in one flank of CDnu/nu 
athymic mice. When tumours reached 100 µl ± 20 µl unlabelled viruses were administrated intra-tumourally 
(3 × 109 vp/injection) on day 1, 3 and 6. Tumour growth was determined with caliper instrument on day 18. 
One-way Anova, Krusaliss Wilkinson post-test *p < 0.01 compared to mock control, 8 animals/group. (B) 
Intravenous administration of 125I-Ad-3∆-A20T (1.83 mBq/vp in 200 µl) and 125I-Ad5wt (3.27 mBq/vp in 200 µl) 
via the tail vein in mice with Suit-2 tumours. Live animals were imaged by SPECT/CT after 24 and 48 h, selected 
images are coronal and transverse views. Tumour uptake was retained up to 48 h (white solid arrows). Open 
arrow indicates the bladder filled with radioactive metabolites, one representative animal, n = 4. The scale for all 
SPECT/CT images is 0.00003–0.00015 kBq.
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48 h after administration suggest that αvβ6-targeting play more important roles in viral spread after subsequent 
rounds of viral replication and cell lysis within the tumour microenvironment. Furthermore, viral replication 
of Ad-3∆-A20T in Suit-2 cells grown in monocultures peaked after 96 h, compared to Ad5wt which peaked at 
48–72 h, producing more viral particles over a longer duration (Fig. 5B). These results verify that after the initial 
distribution of radioactively labelled virus, at the later stage, higher amounts of functional Ad5-3∆-A20T accu-
mulated in tumours compared to Ad5wt. As could be expected radioactivity rapidly declined in all tissues over 
time, reflecting the elimination of labelled capsid proteins once the virus is de-coated and initiates new rounds 
of replication while the tumour-specific targeting and cell lysis is essential for efficient intra-tumoral spread over 
time.
Replication of the oncolytic retargeted Ad-3∆-A20T mutant proceeds at higher levels than 
Ad5wt after systemic delivery. To further validate the biodistribution of radiolabelled viruses, native 
non-labelled Ad-3∆-A20T and Ad5wt were administered via the tail vein in Suit-2 xenografted animals at iden-
tical viral doses. Quantitative PCR revealed that both viruses reached the tumour, spleen and liver tissues at 
24–48 h after systemic administration (Fig. 5C; Supplementary Fig. 5). Relative viral genome amplification was 
determined as fold change obtained by normalising the E1A DNA levels in tumour and spleen to the liver per 
animal. We detected higher levels of viral amplification in tumour tissue compared to liver at both 24 h and 48 h 
Figure 4. Biodistribution of 125I-Ad-3∆-A20T and 125I-Ad5A20 quantified using SPECT/CT images after 
intravenous administration in Suit-2 xenograft models. Tumours, spleen and liver tissues were collected 48 h 
after treatment of animals with 125I-Ad-3∆-A20T and 125I-Ad5wt (n = 4 per group). (A) Tissues were weighed 
and correlated to the respective radioactivity SPECT/CT measurement at each time point, determined by 
ROI analysis using VivoQuant software. Left panel; data were corrected for injected dose (%ID) of radiolabel 
in tumours at 4, 24, and 48 h, and related to tissue weight at the end of the experiment (48 h; n = 4/group). 
Right panel; the radioactivity/g tumour was expressed as percentages of radioactivity/g liver at each timepoint 
(n = 4/group). (B) Radioactivity was measured using a gamma counter at the end of the experiment (48 h) and 
presented as percentages of injected dose (%ID) of labelled virus and relative to tissue weight; n = 3/group.
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time points for Ad-3∆-A20T (Fig. 5D). The retargeted virus was indeed directed more towards the tumour than 
the liver. Conversely, higher viral amplification was detected in liver tissues in animals treated with Ad5wt than 
Ad-3∆-A20T. Upon comparison between both viruses, no significant differences in viral genome quantities were 
detected in the splenic tissues at these low doses reflecting mainly receptor-independent macrophage-mediated 
clearance of virus in this organ7,32. To conclude, Ad-3∆-A20T readily infected tumours at sufficient levels to pro-
mote viral genome amplification while Ad5wt infected hepatic tissue more readily.
Discussion
To date, clinical efficacy with oncolytic adenoviral mutants have been reported following intratumoral admin-
istration however, the major challenge of targeting and eliminating metastatic lesions remains to be addressed. 
The short half-life of adenoviruses in the human circulation is attributable to rapid blood factor binding lead-
ing to immediate hepatic and macrophage mediated elimination, unfavourably decreasing the dose at dis-
tal lesions4,6,7. Several strategies have been used to overcome these obstacles including, capsid modifications, 
polymer-coating33,34 and delivery by mesenchymal stem cells35 to attenuate Factor X-binding, hepatic elimination 
and ablation of erythrocyte- and neutralising antibody-binding10,19,36. Our approach was to retarget our selective 
and potent oncolytic adenovirus Ad∆∆, to αvß6-expressing pancreatic cancers by introducing the high affinity 
A20FMDV integrin-ligand and ablate the CAR and CR-1 binding to erythrocytes, by generating Ad-3∆-A20T12. 
To investigate Ad-3∆-A20T tumor targeting efficiency and biodistribution in longitudinal imaging studies in 
live animals, and to avoid further genetic alterations of the highly modified virus, we established a novel protocol 
for radioactive labelling followed by SPECT/CT analysis. We adapted the Iodogen method for labelling of virus 
with Na125I and demonstrated the feasibility of this approach by monitoring the initial virus uptake in tumor and 
normal tissue in real time.
Figure 5. Viral genome amplification in tumour, liver and spleen tissues after systemic administration of 
Ad-3∆-A20T and Ad5wt. (A) Protein lysates were prepared from tumour and spleen tissues harvested from 
animals treated with viruses (as shown in Fig. 4 with radioactive viruses) at the end of the study (48 h), and 
used for immunoblotting. The early viral E1A protein was detected with a specific anti-E1A antibody. Vinculin 
was detected and used as loading control, one representative cropped immunoblot from each treatment 
group (complete immunoblot in Supplementary Fig. 6). (B) Viral replication of Ad-3∆-A20T and Ad5wt over 
time from 24 h to 192 h, as determined by standard TCID50 assay. Averages (pfu/ml) ± SEM, n = 4. (C) Copy 
numbers of viral genomes in tissue specimens harvested from animals 24 h or 48 h after tail vein administration 
of Ad-3∆-A20T determined by qPCR. Values are expressed as an average copy number of E1A per ng of 
DNA ± SEM in individual animal; n = 4. Tumour (T), spleen (S), liver (L) tissues, M = mouse. (D) Viral genome 
ratios comparing accumulation in tumour and spleen to liver values for both Ad-3∆-A20T and Ad5wt at 24 and 
48 h after tail vein administration. Averages ± SEM, n = 2.
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Several radioactive labeling techniques of proteins and peptides with 125I have been established that are rou-
tinely used to generate trace compounds with high specific activity including the Chloramine T, Iodogen and 
Bolton-Hunter methods21,29,30. While these labeling techniques rarely cause alterations of structure and function 
of proteins and peptides, application of the same conditions to biologically active viruses frequently result in det-
rimental effects to the viral life cycle with greatly reduced viral activity22. To date and to our knowledge, imaging 
of adenoviruses that have been directly radiolabeled have not been feasible. This is largely due to the irreversible 
modifications of the capsid proteins ensued by non-physiological reaction conditions that drastically decrease or 
prevent viral infection, genome amplification and gene expression. In addition, the high protein concentrations 
that promote efficient iodination are not achievable for adenoviruses due to the tendency of virions to aggregate 
at high concentrations25,27. Step-by step modifications of the standard Iodogen iodination conditions enabled 
sufficient incorporation of 125I into adenoviral mutants for preclinical SPECT/CT imaging while preserving viral 
bioactivity. The standard conditions for Iodogen-mediated oxidation of NaI (e.g. basic pH and low salt concen-
trations), significantly reduced viral activity, an outcome most likely caused by structural changes in the fibre and 
other capsid proteins preventing receptor binding and/or cellular internalization. Increasing the buffer capacity, 
avoiding direct exposure of virus to the oxidizing agent and prolonging the reaction time overcame these chal-
lenges resulting in functional virus. Despite lower efficiency of radioisotope incorporation with this adapted pro-
tocol, we were able to determine the initial distribution of several labeled adenoviruses in real time by SPECT/CT 
imaging in two PDAC xenograft models. In contrast to genetically engineered viruses such as those that express 
the human Na/I symporter (hNIS), requiring the modification of each mutant and delivery of 125I or 131I at high 
doses (e.g.37,38), our simpler direct labeling method does not require any genetic engineering and therefore enables 
for quicker results. Similarly, viral mutants expressing EGFP or RFP fluorescent proteins or Luciferase enzymes 
also require genetic modifications and the methods used for detection are generally less sensitive.
Our novel Ad-3∆-A20T mutant was designed to specifically target αvß6-integrin expressing PDAC tumours 
via systemic delivery not only to reach the deep anatomical location of the pancreas within the abdominal cavity 
but also to reach the widespread metastatic sites12,39. Interestingly, both the αvß6-integrin targeted Ad-3∆-A20T 
and the non-targeted Ad5wt viruses reached pancreatic subcutaneous tumours after systemic delivery in mice. It 
is well documented that elimination of adenoviruses takes place at hepatic Kupffer cells in a receptor-independent 
manner which is largely responsible for its short circulatory half-life in mice but also in humans. Human blood 
factors such as Factor X (FX) and IX (FIX) mediate hepatic adenovirus infection by bridging the virus to hep-
aran sulphate proteoglycans (HSPGs) mainly on hepatocytes5,6. However more importantly, Ad5 hepatotoxic-
ity is less severe in humans than in mice possibly due to the entrapping of human erythrocytes by the virus, 
decreasing the rate of hepatocyte uptake and Kupffer cell clearance4. The high affinity binding of Ad5 to CAR 
and CR-1 on erythrocytes in humans does not occur in the murine circulation. In our study, it is therefore likely 
that the apparent similar uptake-rates of Ad5wt and Ad-3∆-A20T in tumours were due to the lack of Ad5wt 
erythrocyte-binding since the ablation of CAR- and CR-1-binding, a “design feature” of the Ad-3∆-A20T could 
not be demonstrated in our murine model as such binding is obsolete in mice. Another reason for the similar 
immediate distribution of radioactivity to the xenografted tumours may be due to the “leaky” vasculature often 
present in tumours. The actions of enhanced permeability and retention (EPR) may have disguised any differ-
ences in initial receptor-mediated cellular uptake of Adwt and Ad-3∆-A20T, whilst also supporting the accumu-
lation of both viruses to the tumour microenvironment. Furthermore, endocytosis of virus within tumour cells 
may not be solely dependent on αvß6-integrin binding, since Suit-2 cells express other receptors important for 
adenoviral binding and internalisation including CAR, αvß3- and αvß5-integrins12. Overall, our findings demon-
strate that in mice, the initial tumour uptake of both 125I-labelled and non-labelled Adwt and Ad-3∆-A20T was 
rapid after systemic delivery. The maximum amount of the tumour-associated radiolabelled virus was reached at 
4–24 h post-administration, but more importantly by 48 h, Ad-3∆-A20T replication proceeded at higher levels 
than Adwt. Presumably, the improved intra-tumoural spread and replication for Ad-3∆-A20T was caused by 
additional rounds of replication in the tumour microenvironment. In support of this assumption, Ad-3∆-A20T 
genomes and E1A expression were present at higher levels than Adwt by 48 h in tumours. In parallel, a decreased 
accumulation of Ad-3∆-A20T, reflecting the reduced genome amplification and replication compared to Adwt in 
liver tissue was observed. Taken together, we demonstrate that systemic delivery of the αvß6-integrin retargeted 
Ad-3∆-A20T virus reached subcutaneous tumour xenografts in athymic mice and propagated more efficiently 
within the tumours than the native Ad5wt virus.
Unfortunately, one limitation of studying adenoviruses in murine models is the lack of viral binding to murine 
erythrocytes and blood factors, which is a major obstacle for delivery in humans. However, we and others previ-
ously demonstrated that the modifications incorporated in Ad-3∆-A20T decreased binding to human erythro-
cytes and Factor IX/complement-4 binding protein (C4BP) which could result in higher circulating levels of virus 
in patients6,20,40. We expect that additional modifications of the virus may be required prior to clinical evaluation 
specifically, modifications of hexon to prevent the binding of neutralising antibodies and/or binding to FX8,10. The 
combination of CAR-binding ablation and specific tumour targeting are effective design strategies that can be 
included in future oncolytic mutants to improve delivery and efficacy in patients with metastatic solid tumours.
To conclude, our findings suggest that radioactive labelling of replicating oncolytic adenoviral mutants is 
an effective approach for studying adenoviruses in a preclinical setting without the need for time-consuming 
genetic modifications nor significantly compromising viral bioactivity. Combined with the SPECT/CT imaging 
vital information such as viral biodistribution, viral elimination rate and any off-target effects over time, all this 
can be recorded in a cost-effective, time-saving manner without affecting data quality. The imaging platform 
is a sensitive tool for studying experimental tumour lesions and may be useful for determining viral uptake in 
orthotopic tumours and otherwise inaccessible tumours in live animals. Further refinements to the method will 
be necessary to enable improved detection. For example, removal of unincorporated label or conjugation of virus 
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to prelabelled prosthetic groups for higher in vivo stability and labelling efficiency. The strategy holds promise for 
efficient selection of viral modifications and mutants prior to more extensive preclinical and clinical applications.
Materials and Methods
tissue culture. Human Pancreatic ductal adenocarcinoma (PDAC) cell lines Suit-2 (Cell Services, Cancer 
Research UK) and Panc04.03 (ATCC, LGC Standards, UK) were cultured at 37 °C and 5% CO2 in Dulbecco 
Modified Eagle’s medium (DMEM)/10% Fetal Bovine Serum (FBS)/1% penicillin and streptomycin (Penicillin 
10000 units/ml, Streptomycin 10 mg/ml; P/S) (Sigma-Aldrich, MO). Cells were regularly monitored for myco-
plasma, and were STR-profiled (LGC Standards and Cancer Research UK) to confirm identical profiles to those 
reported by the suppliers and to the original vial.
Viruses and infections. The viruses used in the study include the previously described modified 
EGFP-expressing mutants generated from species C wild-type adenovirus type 5 (Ad5wt) and Ad5A20 also 
expressing the 20 amino acid FMDV peptide in the fibre11,19. Generation of Ad∆∆ (deleted in E1ACR2 and 
E1B19K) and Ad5-3∆-A20T (Ad∆∆; deleted in E3gp19K, ablated in CAR and CR-1 binding, and expressing the 
FMDV peptide) were previously described11,12. The viruses were produced, purified and characterised according 
to standard protocols11,41. The viral particle (vp) to infectious unit (plaque-forming units; pfu) was 10–50 vp/pfu 
for all viruses. All infections were performed in serum-free DMEM and 2 h later the infection-media was replaced 
with 10% FBS/1% P/S in DMEM.
Radiolabelling of virus. The optimised reaction conditions were as described below. Tris-HCl buffer 
200 mM pH6.8 (1 ml) was added to a precoated Iodogen (1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril) tube 
(ThermoFisher Scientific, UK) and removed, followed by the addition of 20–27 µl of Tris-HCl buffer (200 mM, 
pH6.8) and 25–33.3 µl of Na125I (85–123 MBq) in 0.04 M NaOH (Hartmann GmbH, Germany). After 2 min, the 
reaction mixture was transferred to an aliquot of 200–267 µl of virus (1.23 × 108–2.62 × 1010 vp; 7.2 µg–7.65 µg 
protein) and incubated for another 2 min, 24 °C. The final reaction mixture was pH7.4-7.8. The radiolabelling 
efficiency was measured using iTLC-SG (Agilent, CA) with a mobile phase of 85% MeOH, and exposed on phos-
phor screens, detected by Cyclone (Perkin Elmer, CT) and analysed by the OptiQuant software. The percentage 
of free Na125I and virus-bound 125I was determined. The reaction mixture was diluted with PBS containing 0.01% 
BSA. Aliquots were analysed for viral integrity and function by denaturing polyacrylamide gel electrophoresis 
(SDS-PAGE) and radioactive viral proteins were detected on phosphor screens (Cyclone). In some studies, free 
125I was removed by column purification (Virabind™) according to the manufacturer’s instructions (Cell Biolabs, 
CA) for further analysis of 125I-labelled virus. In these experiments, 10 µg of Tyrosine (Sigma-Aldrich) was added 
to the labelled sample before column purification. Identical reaction protocols using non-radioactive NaI were 
applied to evaluate viral infectivity and replication by flow cytometry, immunoblotting, qPCR and replication 
assays.
immunoblotting. Tumours and spleens were collected from mice and homogenised by sonication in 
ice-cold RIPA Buffer (50 mM Tris-Cl pH8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% 
SDS) supplemented with a protease inhibitor cocktail and PhosSTOP phosphatase inhibitor (Roche Diagnostics, 
Switzerland). The protein concentration of each lysate sample was determined using the BCA assay as per man-
ufacturer’s instructions (ThermoFisher Scientific). To each 20 µg of lysate sample, 2 × Laemmli buffer (0.125 M 
Tris-HCl pH6.8, 20% glycerol, 4% SDS, 0.01% bromophenol blue, 10% β-mercaptoethanol) was added and 
incubated at 95 °C for 5 min. Protein lysates were resolved by SDS-PAGE using the Bio-Rad system (Bio-Rad 
Laboratories Ltd, UK) and transferred onto PVDF membranes (ThermoFisher Scientific). Membranes were incu-
bated with mouse anti-E1A (1:400; M58, GeneTex, TX), and mouse anti-vinculin (1:2000; Abcam, UK) overnight 
at 4 °C in PBS containing 5% non-fat milk and 0.1% Tween (PBS-T). After washing with PBS-T, membranes were 
incubated for 1 h at room temperature with anti-mouse HRP conjugated secondary antibodies (1:2000; Dako, 
UK). Protein bands were detected by enhanced chemiluminescence substrate (ECL; PerkinElmer) and visualised 
using digital capture (iChemi-XT imaging system; Syngene, UK). Densitometric analysis was performed using 
the NIH Image J software.
flow cytometry. Cellular infectivity was quantified by monitoring the percentage of EGFP positive cells 
using flow cytometry. Cells were seeded into 6-well plates (1 × 105cells/well), incubated at 37 °C for 24 h prior to 
infection with EGFP-expressing viruses (Adwt, Ad5A20) for 2 h at 37 °C. The infection media was replaced with 
DMEM/10% FBS, cells were incubated for 24 or 48 h and detached with Trypsin. Detached cells were washed 
twice and resuspended in DMEM/0.1%BSA in preparation for flow cytometry (FACSCalibur, BD Biosciences, 
UK). The percentages of cells detected in the FL1 setting were compared to non-infected cells, acquiring 10,000 
events per sample and analyzed using the FlowJo software 8.8.6 (Tree Star Inc.).
In vivo studies. All in vivo experiments were performed under the approved UK Home Office Project Licence 
P1EE3ECB4 at Barts Cancer Institute in accordance with the Animals Scientific Procedures Act 1986.
In vivo tumour growth and viral tissue distribution. Tumour cells were inoculated subcutaneously in 
one or both flanks of CDnu/nuathymic mice (Charles River, UK) with Suit-2 cells in sterile PBS (1 × 106cells/200 µl) 
and Panc04.03 cells in PBS:Matrigel (Sigma-Aldrich; 1:1) (1 × 106cells/200 µl). Tumour volumes were estimated 
twice weekly by calliper measurements: volume = (length × width2 × π)/6, and animals were monitored and 
treated according to UK Home Office Regulations. When tumours were 110 ± 30 µl animals were randomised to 
treatment groups and administrated the respective virus.
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For viral distribution studies of non-radioactive mutants, purified viruses (Adwt, Ad-3∆-A20T) were admin-
istered via the tail vein with a single injection of 3 × 109 vp in 100 µl. Tumours, spleen and liver were harvested 
24, 48 and 72 h later, homogenised, and protein expression determined by immunoblotting and/or viral DNA 
determined by qPCR.
In vivo magnetic resonance imaging (MRi). In addition to calliper measurements of subcutaneous 
tumours, MRI was used to monitor subcutaneous and internal tumour spread. Mice were imaged by MRI (Bruker 
Icon 1T) on a heated bed to preserve body temperature (36.5–37.5 °C) and were subjected to isoflurane anaesthe-
sia (flow rate of 1.5l/min, maintenance level of 1.5–2%). The anaesthetic level was adjusted so that the respiratory 
rate was approximately 30–60 breaths per minute as measured by a pressure sensitive pad. Respiratory gating was 
also employed to minimise movement artefacts; images were recorded between breaths. Eyes were kept hydrated 
with eye-gel (lubrithal 321/00/12/PUVPT, Dechra). A T2 survey scan was carried out using Paravision 6.0.1 soft-
ware with a repetition time (TR) of 3377 ms and echo time (TE) of 84 ms. For each scan (4 min), 14 slices were 
obtained with a thickness of 1.25 mm and a slice gap of 0.25 mm. Each slice contains 110 × 110 pixels, with a res-
olution of 0.273 × 0.273 mm, corresponding to a field of view of 30 × 30 mm. An estimate of the tumour volume 
and potential internal spread was obtained by drawing 3D regions of interest (ROI) using VivoQuant software 
(version 3.5, InviCRO LLC, MA).
In vivo nano-Spect/ct imaging. For viral distribution studies using radioactive viruses and SPECT/
CT imaging, viral particles (Ad5wt, Ad5A20T and Ad-3∆-A20T, typically 3–8.2 × 109 vp in 100 µl of iodination 
reaction mixture (20 MBq) were administered via the tail vein with a single injection. Thirty minutes prior to 
viral administration, 5 mg NaClO4 in 500 µl PBS was delivered intraperitoneally to each animal to block uptake 
of free iodine via the Na/I symporter (NIS). Animals were anesthetized with 2% Isoflurane gas in air/O2 (1 l/min) 
for whole body imaging at 0.5, 1, 4, 24, and 48 h after virus administration. All studies were performed according 
to UK Home Office Regulations. SPECT-imaging was performed using a NanoSPECT/CT four-head camera 
(Bioscan Inc, Washington D.C.) fitted with 1.4 mm pinhole collimators in helical scanning mode (24 projections, 
40 min acquisition). CT images were acquired with a 45-kVP X-ray source (1500 ms exposure, 180 projections). 
In some studies, a multiple bed system was used to allow three mice to be imaged simultaneously with body 
temperatures maintained at 36.5–37.5 °C via a warm air heating system. Reconstructed images were merged (CT 
recon; InVivoScope Invicro LLC and SPECT recon; HiSPECT, Scivis GmbH, Göttingen, Germany) and the region 
of interest (ROI) was analysed using VivoQuant software (Invicro LLC). 125I activity in tumour, liver and spleen 
was quantified with 3D ROI analysis. Radioactivity in tumours, liver and spleen was corrected for % labelled virus 
injected in each animal and normalized to the weight of the tumour at the end of the study. For liver tissues repre-
sentative fixed liver volumes were used for the 3D ROI analysis. After completion of the 48 h imaging time-points 
tumours, liver and spleens were collected, weighed and processed for immunoblotting, and radioactivity was 
quantified using a Compugamma CS counter (LKB Instruments, Australia).
Quantitative pcR. Whole tumour, spleen and liver tissues were removed and collected from mice at 24–72 h 
after tail vein administration of Adwt or Ad5–3∆-A20T. Serum free media (500 µl) were added to tissue speci-
mens and were mechanically dispersed in cell strainers (70 µM, Falcon). Samples were lysed in 200 µl lysis buffer 
(ATL buffer) provided in the DNA extraction kit (DNeasy Blood and Tissue kit, Qiagen). Double-stranded DNA 
extraction proceeded according to the manufacturer’s instructions after determining quality and quantity of har-
vested DNA (Nanodrop; ThermoFisher, Scientific, UK). Quantitative PCR was performed using 20 µg of extracted 
DNA in 20 µl reaction mixture containing Power SYBR Green Mastermix (ThermoFisher). Relative changes in 
viral DNA amplification was determined by the ∆∆CT method relating the DNA levels in tumour and spleen 
to the liver levels in each animal. The following primers were used: E2A F (5′-GGA TAC AGC GCC TGC ATA 
AAA G-3′); E2A R (5′-CCA ATC AGT TTT CCG GCA AGT-3′); GAPDH F (5′ TGG GCT ACA CTG AGC ACC 
AG-3′) and GAPDH R (5′ GGG TGT CGC TGT TGA AGT CA-3′). For absolute quantification of viral genomes 
in the same tissue specimens, a standard curve was generated using pure genomic Ad5wt DNA as template. The 
following primers were used: E1A F 5′ TGT ACC GGA GGT GAT CGA TCT 3′; E1A R′ TCG TCA CTG GGT 
GGA AAG C 3′. The thermal cycling profile were: 2 min at 50 °C, 10 min at 95 °C and 40 cycles of 15s at 95 °C and 
1 min of 60 °C. Assays were performed in MicroAmp Optical 96-Well plates and Real-Time PCR system 7500 
(Applied Biosystems, CA).
Viral replication by the 50% tissue culture infectious dose (TCID50) assay. Suit-2 cells were seeded 
into 6 well plates at 1 × 105 cells/well and after 24 h, cells were infected with 100 particles per cell (ppc) of Ad5-
3∆-A20T. Cell culture media and cells containing virus were collected and freeze-thawed three times in liquid 
nitrogen at 24 h–192 h post infection. Viral samples were serially diluted in 96-well plates containing A549 cells 
(1 × 104/well) as detector cells. Viral replication was determined as previously described for TCID50 assays11,12.
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